Report Detail

Pharma & Healthcare Global Tumor Necrosis Factor Inhibitors Drug Market Research Report 2019

  • RnM2745050
  • |
  • 09 January, 2019
  • |
  • Global
  • |
  • 149 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

This report studies the global Tumor Necrosis Factor Inhibitors Drug market status and forecast, categorizes the global Tumor Necrosis Factor Inhibitors Drug market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia).

The major manufacturers covered in this report
Apogenix
AryoGen Biopharma
Bionovis
CASI Pharmaceuticals
Celltrion
Celgene Corporation
Delenex Therapeutics
Dexa Medica
EPIRUS Biopharmaceuticals
Janssen Biotech
GlaxoSmithKline
HanAll Biopharma
Intas Pharmaceuticals
LEO Pharma
LG Life Sciences
MedImmune
Momenta Pharmaceuticals
Novartis
PROBIOMED
Reliance Life Sciences
Sandoz
Samsung Bioepis
Sanofi-Aventis
Shanghai CP Guojian Pharmaceutical
Shanghai Pharmaceuticals
Simcere Pharmaceutical
Toyama Chemical
Tsumura
UCB
Zydus Cadila

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering
North America
Europe
China
Japan
Southeast Asia
India

We can also provide the customized separate regional or country-level reports, for the following regions:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Rest of Asia-Pacific
Europe
Germany
France
UK
Italy
Spain
Russia
Rest of Europe
Central & South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Saudi Arabia
Turkey
Rest of Middle East & Africa

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Cimzia (Certolizumab Pegol)
Enbrel (Etanercept)
Humira ( Adalimumab)
Otezla (Apremilast)
Remicade (Infliximab)
Simponi (Golimumab)
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
Clinic
Hospital
Others

The study objectives of this report are:
To analyze and study the global Tumor Necrosis Factor Inhibitors Drug capacity, production, value, consumption, status (2013-2017) and forecast (2018-2025);
Focuses on the key Tumor Necrosis Factor Inhibitors Drug manufacturers, to study the capacity, production, value, market share and development plans in future.
Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
To define, describe and forecast the market by type, application and region.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Tumor Necrosis Factor Inhibitors Drug are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders
Tumor Necrosis Factor Inhibitors Drug Manufacturers
Tumor Necrosis Factor Inhibitors Drug Distributors/Traders/Wholesalers
Tumor Necrosis Factor Inhibitors Drug Subcomponent Manufacturers
Industry Association
Downstream Vendors

Available Customizations
With the given market data, QYResearch offers customizations according to the company's specific needs. The following customization options are available for the report:
Regional and country-level analysis of the Tumor Necrosis Factor Inhibitors Drug market, by end-use.
Detailed analysis and profiles of additional market players.


Table of Contents

    Global Tumor Necrosis Factor Inhibitors Drug Market Research Report 2018

      1 Tumor Necrosis Factor Inhibitors Drug Market Overview

      • 1.1 Product Overview and Scope of Tumor Necrosis Factor Inhibitors Drug
      • 1.2 Tumor Necrosis Factor Inhibitors Drug Segment by Type (Product Category)
        • 1.2.1 Global Tumor Necrosis Factor Inhibitors Drug Production and CAGR (%) Comparison by Type (Product Category)(2013-2025)
        • 1.2.2 Global Tumor Necrosis Factor Inhibitors Drug Production Market Share by Type (Product Category) in 2017
        • 1.2.3 Cimzia (Certolizumab Pegol)
        • 1.2.3 Enbrel (Etanercept)
        • 1.2.5 Humira ( Adalimumab)
        • 1.2.6 Otezla (Apremilast)
        • 1.2.7 Remicade (Infliximab)

      Simponi (Golimumab)

      • 1.3 Global Tumor Necrosis Factor Inhibitors Drug Segment by Application
        • 1.3.1 Tumor Necrosis Factor Inhibitors Drug Consumption (Sales) Comparison by Application (2013-2025)
        • 1.3.2 Clinic
        • 1.3.3 Hospital
        • 1.3.4 Others
      • 1.4 Global Tumor Necrosis Factor Inhibitors Drug Market by Region (2013-2025)
        • 1.4.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size (Value) and CAGR (%) Comparison by Region (2013-2025)
        • 1.4.2 North America Status and Prospect (2013-2025)
        • 1.4.3 Europe Status and Prospect (2013-2025)
        • 1.4.4 China Status and Prospect (2013-2025)
        • 1.4.5 Japan Status and Prospect (2013-2025)
        • 1.4.6 Southeast Asia Status and Prospect (2013-2025)
        • 1.4.7 India Status and Prospect (2013-2025)
      • 1.5 Global Market Size (Value) of Tumor Necrosis Factor Inhibitors Drug (2013-2025)
        • 1.5.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue Status and Outlook (2013-2025)
        • 1.5.2 Global Tumor Necrosis Factor Inhibitors Drug Capacity, Production Status and Outlook (2013-2025)

      2 Global Tumor Necrosis Factor Inhibitors Drug Market Competition by Manufacturers

      • 2.1 Global Tumor Necrosis Factor Inhibitors Drug Capacity, Production and Share by Manufacturers (2013-2018)
        • 2.1.1 Global Tumor Necrosis Factor Inhibitors Drug Capacity and Share by Manufacturers (2013-2018)
        • 2.1.2 Global Tumor Necrosis Factor Inhibitors Drug Production and Share by Manufacturers (2013-2018)
      • 2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue and Share by Manufacturers (2013-2018)
      • 2.3 Global Tumor Necrosis Factor Inhibitors Drug Average Price by Manufacturers (2013-2018)
      • 2.4 Manufacturers Tumor Necrosis Factor Inhibitors Drug Manufacturing Base Distribution, Sales Area and Product Type
      • 2.5 Tumor Necrosis Factor Inhibitors Drug Market Competitive Situation and Trends
        • 2.5.1 Tumor Necrosis Factor Inhibitors Drug Market Concentration Rate
        • 2.5.2 Tumor Necrosis Factor Inhibitors Drug Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue (Value) by Region (2013-2018)

      • 3.1 Global Tumor Necrosis Factor Inhibitors Drug Capacity and Market Share by Region (2013-2018)
      • 3.2 Global Tumor Necrosis Factor Inhibitors Drug Production and Market Share by Region (2013-2018)
      • 3.3 Global Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Market Share by Region (2013-2018)
      • 3.4 Global Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
      • 3.5 North America Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
      • 3.6 Europe Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
      • 3.7 China Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
      • 3.8 Japan Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
      • 3.9 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
      • 3.10 India Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)

      4 Global Tumor Necrosis Factor Inhibitors Drug Supply (Production), Consumption, Export, Import by Region (2013-2018)

      • 4.1 Global Tumor Necrosis Factor Inhibitors Drug Consumption by Region (2013-2018)
      • 4.2 North America Tumor Necrosis Factor Inhibitors Drug Production, Consumption, Export, Import (2013-2018)
      • 4.3 Europe Tumor Necrosis Factor Inhibitors Drug Production, Consumption, Export, Import (2013-2018)
      • 4.4 China Tumor Necrosis Factor Inhibitors Drug Production, Consumption, Export, Import (2013-2018)
      • 4.5 Japan Tumor Necrosis Factor Inhibitors Drug Production, Consumption, Export, Import (2013-2018)
      • 4.6 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Production, Consumption, Export, Import (2013-2018)
      • 4.7 India Tumor Necrosis Factor Inhibitors Drug Production, Consumption, Export, Import (2013-2018)

      5 Global Tumor Necrosis Factor Inhibitors Drug Production, Revenue (Value), Price Trend by Type

      • 5.1 Global Tumor Necrosis Factor Inhibitors Drug Production and Market Share by Type (2013-2018)
      • 5.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue and Market Share by Type (2013-2018)
      • 5.3 Global Tumor Necrosis Factor Inhibitors Drug Price by Type (2013-2018)
      • 5.4 Global Tumor Necrosis Factor Inhibitors Drug Production Growth by Type (2013-2018)

      6 Global Tumor Necrosis Factor Inhibitors Drug Market Analysis by Application

      • 6.1 Global Tumor Necrosis Factor Inhibitors Drug Consumption and Market Share by Application (2013-2018)
      • 6.2 Global Tumor Necrosis Factor Inhibitors Drug Consumption Growth Rate by Application (2013-2018)
      • 6.3 Market Drivers and Opportunities
        • 6.3.1 Potential Applications
        • 6.3.2 Emerging Markets/Countries

      7 Global Tumor Necrosis Factor Inhibitors Drug Manufacturers Profiles/Analysis

      • 7.1 Apogenix
        • 7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.1.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
          • 7.1.2.1 Product A
          • 7.1.2.2 Product B
        • 7.1.3 Apogenix Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.1.4 Main Business/Business Overview
      • 7.2 AryoGen Biopharma
        • 7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.2.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
          • 7.2.2.1 Product A
          • 7.2.2.2 Product B
        • 7.2.3 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.2.4 Main Business/Business Overview
      • 7.3 Bionovis
        • 7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.3.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
          • 7.3.2.1 Product A
          • 7.3.2.2 Product B
        • 7.3.3 Bionovis Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.3.4 Main Business/Business Overview
      • 7.4 CASI Pharmaceuticals
        • 7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.4.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
          • 7.4.2.1 Product A
          • 7.4.2.2 Product B
        • 7.4.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.4.4 Main Business/Business Overview
      • 7.5 Celltrion
        • 7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.5.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
          • 7.5.2.1 Product A
          • 7.5.2.2 Product B
        • 7.5.3 Celltrion Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2015-2018)
        • 7.5.4 Main Business/Business Overview
      • 7.6 Celgene Corporation
        • 7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.6.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
          • 7.6.2.1 Product A
          • 7.6.2.2 Product B
        • 7.6.3 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.6.4 Main Business/Business Overview
      • 7.7 Delenex Therapeutics
        • 7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.7.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
          • 7.7.2.1 Product A
          • 7.7.2.2 Product B
        • 7.7.3 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.7.4 Main Business/Business Overview
      • 7.8 Dexa Medica
        • 7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.8.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
          • 7.8.2.1 Product A
          • 7.8.2.2 Product B
        • 7.8.3 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.8.4 Main Business/Business Overview
      • 7.9 EPIRUS Biopharmaceuticals
        • 7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.9.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
          • 7.9.2.1 Product A
          • 7.9.2.2 Product B
        • 7.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.9.4 Main Business/Business Overview
      • 7.8 Janssen Biotech
        • 7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.10.2 Tumor Necrosis Factor Inhibitors Drug Product Category, Application and Specification
          • 7.10.2.1 Product A
          • 7.10.2.2 Product B
        • 7.10.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.10.4 Main Business/Business Overview
      • 7.11 GlaxoSmithKline
      • 7.12 HanAll Biopharma
      • 7.13 Intas Pharmaceuticals
      • 7.14 LEO Pharma
      • 7.15 LG Life Sciences
      • 7.16 MedImmune
      • 7.17 Momenta Pharmaceuticals
      • 7.18 Novartis
      • 7.19 PROBIOMED
      • 7.20 Reliance Life Sciences
      • 7.21 Sandoz
      • 7.22 Samsung Bioepis
      • 7.23 Sanofi-Aventis
      • 7.24 Shanghai CP Guojian Pharmaceutical
      • 7.25 Shanghai Pharmaceuticals
      • 7.26 Simcere Pharmaceutical
      • 7.27 Toyama Chemical
      • 7.28 Tsumura
      • 7.29 UCB
      • 7.30 Zydus Cadila

      8 Tumor Necrosis Factor Inhibitors Drug Manufacturing Cost Analysis

      • 8.1 Tumor Necrosis Factor Inhibitors Drug Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
        • 8.1.4 Market Concentration Rate of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
        • 8.2.1 Raw Materials
        • 8.2.2 Labor Cost
        • 8.2.3 Manufacturing Expenses
      • 8.3 Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitors Drug

      9 Industrial Chain, Sourcing Strategy and Downstream Buyers

      • 9.1 Tumor Necrosis Factor Inhibitors Drug Industrial Chain Analysis
      • 9.2 Upstream Raw Materials Sourcing
      • 9.3 Raw Materials Sources of Tumor Necrosis Factor Inhibitors Drug Major Manufacturers in 2017
      • 9.4 Downstream Buyers

      10 Marketing Strategy Analysis, Distributors/Traders

      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
        • 10.1.3 Marketing Channel Development Trend
      • 10.2 Market Positioning
        • 10.2.1 Pricing Strategy
        • 10.2.2 Brand Strategy
        • 10.2.3 Target Client
      • 10.3 Distributors/Traders List

      11 Market Effect Factors Analysis

      • 11.1 Technology Progress/Risk
        • 11.1.1 Substitutes Threat
        • 11.1.2 Technology Progress in Related Industry
      • 11.2 Consumer Needs/Customer Preference Change
      • 11.3 Economic/Political Environmental Change

      12 Global Tumor Necrosis Factor Inhibitors Drug Market Forecast (2018-2025)

      • 12.1 Global Tumor Necrosis Factor Inhibitors Drug Capacity, Production, Revenue Forecast (2018-2025)
        • 12.1.1 Global Tumor Necrosis Factor Inhibitors Drug Capacity, Production and Growth Rate Forecast (2018-2025)
        • 12.1.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue and Growth Rate Forecast (2018-2025)
        • 12.1.3 Global Tumor Necrosis Factor Inhibitors Drug Price and Trend Forecast (2018-2025)
      • 12.2 Global Tumor Necrosis Factor Inhibitors Drug Production, Consumption , Import and Export Forecast by Region (2018-2025)
        • 12.2.1 North America Tumor Necrosis Factor Inhibitors Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
        • 12.2.2 Europe Tumor Necrosis Factor Inhibitors Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
        • 12.2.3 China Tumor Necrosis Factor Inhibitors Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
        • 12.2.4 Japan Tumor Necrosis Factor Inhibitors Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
        • 12.2.5 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
        • 12.2.6 India Tumor Necrosis Factor Inhibitors Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
      • 12.3 Global Tumor Necrosis Factor Inhibitors Drug Production, Revenue and Price Forecast by Type (2018-2025)
      • 12.4 Global Tumor Necrosis Factor Inhibitors Drug Consumption Forecast by Application (2018-2025)

      13 Research Findings and Conclusion

        14 Appendix

        • 14.1 Methodology/Research Approach
          • 14.1.1 Research Programs/Design
          • 14.1.2 Market Size Estimation
          • 14.1.3 Market Breakdown and Data Triangulation
        • 14.2 Data Source
          • 14.2.1 Secondary Sources
          • 14.2.2 Primary Sources

        Summary:
        Get latest Market Research Reports on Tumor Necrosis Factor Inhibitors Drug . Industry analysis & Market Report on Tumor Necrosis Factor Inhibitors Drug is a syndicated market report, published as Global Tumor Necrosis Factor Inhibitors Drug Market Research Report 2019. It is complete Research Study and Industry Analysis of Tumor Necrosis Factor Inhibitors Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

        Last updated on

        REPORT YOU MIGHT BE INTERESTED

        Purchase this Report

        $2,900.00
        $5,800.00
        2,320.00
        4,640.00
        2,699.90
        5,399.80
        450,689.00
        901,378.00
        242,150.00
        484,300.00
        Credit card Logo

        Related Reports


        Reason to Buy

        Request for Sample of this report